Supplementary Material for: Pembrolizumab induced rhabdomyolysis in a clear cell renal cell carcinoma patient: a case report

Pembrolizumab is one of the approved treatments for many types of cancer including clear cell renal cell carcinoma (ccRCC). It has improved the prognosis of renal cell carcinoma (RCC) yet has many possible immune related side effects. We discuss a rare case of rhabdomyolysis in an ccRCC patient treated with Pembrolizumab. The case was complicated with acute kidney injury and severe hypothyroidism, which we can be attributed to Pembrolizumab.